Dexcom President and CEO Jake Leach (right) and Executive Chair Kevin Sayer [Photo courtesy of Dexcom]
Dexcom was the world’s 30th-largest medical device company on our latest Medtech Big 100 ranking by revenue. That ranking was based on the diabetes tech developer’s 2024 revenue of $4.03 billion. Dexcom reported $4.66 billion in revenue for 2025, up 15% from the year before.
Recruiting and retaining top talent — both at the executive and engineering level — is crucial in the medtech industry, but employee compensation is kept secret in most cases. Medical Design & Outsourcing tracks and analyzes these pay figures when disclosed by major device developers and manufacturers.
Dexcom’s CEO change was one of the medical device industry’s top personnel moves in medtech of 2025. And what a year it was for Jake Leach, the former Medtronic electrical engineer who joined Dexcom in 2004 and rose through the R&D ranks to SVP and then chief technology officer.
Leach started 2025 as Dexcom EVP and chief operating officer, then added president to his title in May, and was announced as the successor to Kevin Sayer in July.
Sayer planned to retire as CEO and become executive chair when Dexcom started its next fiscal year on Jan. 1, 2026, with Leach set to take over at that time. But Sayer took medical leave in September 2025 and Leach stepped up early as interim principal executive officer.
Leach officially started as president and CEO in January 2026 and soon after became chair of chair of the AdvaMed Diabetes Sector. Sayer returned from his leave in March 2026 as executive chair.
MDO Senior Editor Sean Whooley recently caught up with Leach during the American Diabetes Association Scientific Sessions (ADA) 2026. Read more from Whooley’s Dexcom coverage at Drug Delivery Business News.
Dexcom Chair Kevin Sayer [Photo courtesy of Dexcom]
Dexcom executive pay
The U.S. Securities and Exchange Commission requires publicly held companies to disclose total compensation for their CEO, CFO and three of the highest-paid executives.
Sayer received $16.3 million in total compensation for 2025, up 3% from $15.8 million the year before. His 2025 compensation included $1.2 million in salary, $13.9 million in stock awards, a $1.1 million cash performance bonus and $70,854 in other compensation.
His other compensation included $42,586 worth of personal security costs, $13,913 in travel, meal and other expenses “considered to be taxable income associated with the attendance of the executive’s spouse at certain company events,” and $14,354 in related tax gross-ups “on the imputed income attributed to the spouse or guest’s travel or entertainment.”
Dexcom CEO Jake Leach [Photo courtesy of Dexcom]
Leach’s 2025 compensation included $768,962 in salary, $5.9 million in stock awards, a $1.2 million cash performance bonus and $116,156 in other compensation.
That other compensation included $105,379 worth of personal security costs and $10,777 in 401(k) plan matching contributions. Dexcom provides personal security arrangements for all named executives.
“While we do not consider personal security measures to be a personal benefit, but instead appropriate expenses for the benefit of the company that arise out of our executives’ employment responsibilities and that are necessary to his or her job performance and to ensure the safety of our executives and their family, SEC regulations require the costs of certain personal security arrangements to be reported as personal benefits.” Dexcom said in the filing.
Dexcom EVP and CFO Jereme Sylvain [Photo courtesy of Dexcom]
Sylvain’s compensation included a $646,623 salary, $5.9 million in stock awards, a $465,568 cash performance bonus and $29,649 in other compensation.
His other compensation included $19,149 worth of personal security costs and $10,500 in 401(k) matching contributions.
Dexcom EVP and Chief Commercial Officer Jon Coleman [Photo courtesy of Dexcom]
Coleman’s compensation included a $491,507 salary, $5.8 million in stock awards, a $353,885 cash performance bonus and $68,858 in other compensation.
His other compensation included $58,358 worth of personal security costs and $10,500 in 401(k) matching contributions.
Dexcom EVP and Chief Legal Officer Michael Brown [Photo courtesy of Dexcom]
Brown’s compensation included a $631,627 salary, $5.2 million in stock awards, a $454,771 cash performance bonus and $14,963 in other compensation.
His other compensation included $4,463 worth of personal security costs and $10,500 in 401(k) matching contributions.
Dexcom EVP and Chief Human Resources Officer Sadie Stern received $6.3 million in total compensation for 2025, up 28% from $4.9 million the year before.
Dexcom EVP and Chief Human Resources Officer Sadie Stern [Photo courtesy of Dexcom]
Her other compensation included $18,752 worth of personal security costs and $9,405 in 401(k) matching contributions.
“We have designed our executive compensation programs to support our near-term financial and strategic objectives and promote the long-term growth of our company, including long-term share price appreciation,” the company said in the filing.
Check out MDO’s May 2026 issue: Fighting diabetes with next-gen sensors and drug delivery devices
Dexcom’s median worker pay and CEO pay ratio
The SEC requires publicly traded companies to calculate the gap between CEO compensation and pay for its median employee.
Decxom calculated its median employee wage at $58,663 for 2025, excluding Sayer and Leach’s 2025 compensation. In its previous annual filing, Dexcom reported its median employee compensation as $114,213 for 2024 (this figured included Leach’s 2024 compensation because he was not yet CEO or interim principal executive officer).
The company provided a pay ratio between its median employee and both Sayer and Leach’s 2025 compensation since they both served as principal executive officers during fiscal 2025.
The latest median employee pay figure puts Sayer’s pay ($16.3 million) at 278 times more than Dexcom’s median employee, and Leach’s pay (nearly $8 million) at 136 times more than the median employee.
At other medtech companies that offer more details about their median workers than required by the SEC pay disclosure rules, those median medtech workers often hold technical roles such as device design or engineering.
Shareholders overwhelmingly voted in support of the company’s executive pay at Dexcom’s annual meeting in May 2026.
For more medtech industry analysis and tips from medical device experts, sign up for our free twice-weekly newsletter, and if you’re a medical device industry professional you’re likely also eligible for a free subscription to our magazine online and by mail.
More medtech compensation analysis for CEOs, top-paid executives and median workers
- Solventum executive pay disclosure includes $11M severance for ex-MedSurg leader
- Edwards Lifesciences reports double-digit pay increases for executives and median employee
- Zimmer Biomet discloses executive pay and double-digit increase for its median employee
- Siemens Healthineers CEO and HR leader got double-digit pay increases
- Alcon increases executive comp budget to close ‘transatlantic pay gap’
- Accendra Health (formerly Owens & Minor) discloses executive pay
- Baxter discloses executive pay under new CEO and golden parachute for the last CEO
- Stryker pay drops for top executives and the median employee
- Henry Schein discloses exec pay for longtime CEO Stan Bergman’s final year
- Abbott’s device leader pay climbs again with double-digit sales growth
- Medtech CDMO Integer discloses executive pay after new CEO steps in
- Cardinal Health reported a big increase in median worker pay
- GE HeathCare discloses CEO pay decrease but increases for other execs and the median employee
- BD reports lower CEO pay but increases for other execs and the median worker
- Johnson & Johnson discloses executive pay, denies them a talc fight ‘windfall’
- Boston Scientific CEO pay rises again along with median employee pay
- Intuitive discloses CEO pay with new leader at the helm
- Medtronic discloses pay for Diabetes leaders ahead of MiniMed IPO
